Skip to main content
. 2015 Jun 25;6(29):27478–27489. doi: 10.18632/oncotarget.4393

Figure 6. PSB1115 enhances the effects of anti-VEGF treatment by reducing tumor CD11b+Gr1+ cells accumulation.

Figure 6

A. Mice inoculated with B16.F10 melanoma cells were treated with PSB1115 or vehicle in combination with anti-VEGF antibody (150 μg/mouse). Tumor volume was measured at various times during treatment. B, C and D. percentage of MDSCs or CD3+NK1.1+ cells or CD3+CD8+ T cells, respectively, analyzed by FACS in melanoma tissues of mice treated as above. Data are from three independent experiments and represent mean ± SEM (n = 9–12 per group). *p < 0.05, **p < 0.01.